| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,974,661 ) |
| | 2024 | 2024 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 000 | 4 | NIH | 2/8/2024 | $974,661 |
| | 2024 | 2024 | EMMUNE INC | 620 MEMORIAL DR STE W-100 | CAMBRIDGE | MA | 02139-4981 | MIDDLESEX | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 000 | 3 | NIH | 7/18/2024 | $1,000,000 |
| | 2024 | 2023 | EMMUNE INC | 620 MEMORIAL DR STE W-100 | CAMBRIDGE | MA | 02139-4981 | MIDDLESEX | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 000 | 3 | NIH | 7/11/2024 | $0 |
| | 2024 | 2023 | EMMUNE INC | 620 MEMORIAL DR STE W-100 | CAMBRIDGE | MA | 02139-4981 | MIDDLESEX | USA | R44AI170285 | Process development for manufacturing eCD4-Ig | 000 | 1 | NIH | 3/27/2024 | $0 |
| | 2024 | 2022 | EMMUNE INC | 620 MEMORIAL DR STE W-100 | CAMBRIDGE | MA | 02139-4981 | MIDDLESEX | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 000 | 4 | NIH | 2/20/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,312,170 ) |
| | 2023 | 2023 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 000 | 3 | NIH | 2/10/2023 | $1,000,000 |
| | 2023 | 2023 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI170285 | Process development for manufacturing eCD4-Ig | 000 | 1 | NIH | 12/22/2022 | $299,998 |
| | 2023 | 2023 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 001 | 3 | NIH | 2/16/2023 | $1,012,172 |
| | 2023 | 2023 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 002 | 2 | NIH | 8/17/2023 | $1,000,000 |
| | 2023 | 2022 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 001 | 1 | NIH | 7/3/2023 | $0 |
| | 2023 | 2022 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 000 | 1 | NIH | 2/3/2023 | $0 |
| | 2023 | 2020 | EMMUNE INC | 14155 US HIGHWAY 1 | JUNO BEACH | FL | 33408-1442 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 000 | 1 | NIH | 12/20/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,194,221 ) |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 000 | 1 | NIH | 8/8/2022 | $300,000 |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI170392 | SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | 001 | 1 | NIH | 8/11/2022 | $0 |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 001 | 2 | NIH | 2/17/2022 | $1,012,172 |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 002 | 2 | NIH | 3/1/2022 | $0 |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 001 | 2 | NIH | 3/9/2022 | $974,663 |
| | 2022 | 2022 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 001 | 4 | NIH | 4/15/2022 | $907,386 |
| | 2022 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 000 | 3 | NIH | 1/14/2022 | $0 |
| | 2022 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 000 | 1 | NIH | 11/4/2021 | $0 |
| | 2022 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 002 | 1 | NIH | 6/7/2022 | $0 |
| | 2022 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI134269 | Development of AAV vectors for long-term expression of eCD4-Ig | 000 | 4 | NIH | 4/15/2022 | $0 |
| | 2022 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 000 | 1 | NIH | 12/28/2021 | $0 |
| | 2022 | 2018 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI124832 | WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | 000 | 3 | NIH | 10/22/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,203,047 ) |
| | 2021 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 004 | 3 | NIH | 4/16/2021 | $870,946 |
| | 2021 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI165255 | Glycoengineering eCD4-Ig | 000 | 1 | NIH | 7/13/2021 | $300,000 |
| | 2021 | 2021 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 001 | 1 | NIH | 1/25/2021 | $32,101 |
| | 2021 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 000 | 1 | NIH | 1/25/2021 | $0 |
| | 2021 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 002 | 2 | NIH | 4/14/2021 | $657 |
| | 2021 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 002 | 1 | NIH | 4/14/2021 | $0 |
| | 2021 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 006 | 2 | NIH | 9/15/2021 | -$657 |
| | 2021 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 000 | 2 | NIH | 4/13/2021 | $0 |
| | 2021 | 2019 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 003 | 1 | NIH | 4/15/2021 | $0 |
| | 2021 | 2019 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 001 | 1 | NIH | 4/14/2021 | -$657 |
| | 2021 | 2019 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 005 | 1 | NIH | 9/15/2021 | $657 |
| | 2021 | 2018 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI124832 | WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | 000 | 3 | NIH | 9/2/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,178,445 ) |
| | 2020 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44TR003501 | Engineering AAV capsids for enhanced transduction of skeletal muscle | 000 | 1 | NIH | 8/18/2020 | $292,899 |
| | 2020 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI134269 | Development of AAV vectors for long-term expression of eCD4-Ig | 000 | 4 | NIH | 7/20/2020 | $999,443 |
| | 2020 | 2020 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 000 | 2 | NIH | 5/19/2020 | $886,103 |
| | 2020 | 2018 | EMMUNE, INC. | 14155 US HIGHWAY 1 JUNO BEACH | JUNO BEACH | FL | 33408 | PALM BEACH | USA | R44AI124832 | WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | 000 | 3 | NIH | 2/6/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,299,675 ) |
| | 2019 | 2019 | EMMUNE, INC. | 130 SCRIPPS WAY BLDG B ROOM 112 | JUPITER | FL | 33458-5284 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 001 | 1 | NIH | 8/6/2019 | $0 |
| | 2019 | 2019 | EMMUNE, INC. | 130 SCRIPPS WAY BLDG B ROOM 112 | JUPITER | FL | 33458-5284 | PALM BEACH | USA | R44AI145491 | Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | 000 | 1 | NIH | 7/30/2019 | $300,000 |
| | 2019 | 2019 | EMMUNE, INC. | 130 SCRIPPS WAY BLDG B ROOM 112 | JUPITER | FL | 33458-5284 | PALM BEACH | USA | R44AI134269 | Development of AAV vectors for long-term expression of eCD4-Ig | 000 | 3 | NIH | 7/17/2019 | $999,675 |
| | 2019 | 2018 | EMMUNE, INC. | 130 SCRIPPS WAY BLDG B ROOM 112 | JUPITER | FL | 33458-5284 | PALM BEACH | USA | R43AI136163 | Cpf1-mediated inactivation of an AAV transgene | 000 | 1 | NIH | 5/29/2019 | $0 |
|
|
